Oncology Clinical Trials Market Share, Size, Trends, Industry Analysis Report, By Phase (Phase I, Phase II, Phase III, Phase IV); By Study Design (Interventional, Observational, Expanded Access); By Cancer Type; By Region; Segment Forecast, 2021 - 2028

Published Date: May 2021
Pages: 117
格式：PDF.
报告ID：PM1895
基数：2020
Historical Data: 2016-2019

报告摘要

全球肿瘤学临床试验市场于2020年的价值为110.2亿美元，预计预测期内的CAGR增长率为5.6％。市场主要受癌症病例数量上升，需要定制药物的需求，以及对肿瘤的研发活动的增加。此外，肿瘤学领域和支持政府方案的进展也在推动肿瘤临床试验的需求。

了解有关此报告的更多信息：request for sample pages

The number of people diagnosed with cancer is predicted to multiply in the coming years. While the number of survivors has risen considerably due to oncology studies, the number of cancer patients is projected to rise worldwide. Lung cancer is the leading cause of cancer death, with an estimated 1.8 million people diagnosed each year worldwide.

Industry Dynamics

Growth Drivers
A large number of unmet health needs have also been reported in developing countries due to the high prevalence of cancer in the region. For example, according to figures published by the World Health Organization, Cancer is the world's second leading cause of death in 2018 and is blamed for an estimated 9.6 million deaths in 2018.

肿瘤学临床三市场的增长als is due to favorable government and non-government initiatives that fund cancer research. For example, the National Cancer Institute is running a variety of clinical trials projects and initiatives to promote clinical research. Study on cancer care is now going ahead at a rapid rate.

肿瘤学临床试验市场报告范围

The market is primarily segmented on the basis of phase, study design, cancer type, and region.

逐阶段	通过研究设计	通过癌症类型	按地区
第一阶段I. 第一阶段I.I 第三阶段第一阶段I.V	介入 Observational 扩展访问	肺癌乳腺癌 Thyroid cancer 白血病肝癌 Skin cancer Lymphoma Pancreatic cancer 前列腺癌结肠和直肠癌泌尿系统癌症其他癌症	北美（美国，加拿大）欧洲（法国，德国，英国，意大利，西班牙，荷兰，奥地利） Asia Pacific (Japan, China, India, Malaysia, Indonesia, South Korea) 拉丁美洲（巴西，墨西哥，阿根廷）中东和非洲（沙特阿拉伯，阿联酋，以色列，南非）

了解有关此报告的更多信息：request for sample pages

阶段洞察

Based upon phase, the global oncology clinical trials market is categorized into Phase I, Phase II, Phase III, and Phase IV. The phase II market segment held the largest share in the global market in 2020. The market segment is also expected to retain its role during the forecast period. This is due to a growing number of phase II studies.

此外，与试验努力相比，肿瘤学临床试验的整体生产率计算为成功率，自2010年以来已增加22％。药物医疗保健产品监管机构（MHRA）的II期和第III期试验也增加了5.5yabo娱乐vip％2011年和2016年之间。

In addition, there was a late-stage expansion of the drug pipeline to oncology by 19.0% in 2018 alone. The number of targeted therapies in the pipeline rose to 849 in 2018 from 711 in 2019. In 2018, 91.0% of the late-stage oncology pipeline was biotherapy and targeted small molecules. Approximately 711 companies work on 849 drugs, most of them from emerging biopharmaceutical companies.

癌症类型的洞察力

白血病市场部门在2020年的全球肿瘤临床试验市场的收入份额最大。这是由于全球血液越来越多的癌症。据估计，血癌新患者占美国市场统计中诊断的10.0％的总体癌症病例，展示了美国血癌的趋势，趋势在全球相似。

2017年，白血病在婴儿中普遍存在癌症，占所有早期癌症的30％左右。根据美国临床肿瘤学会（ASCO），多种骨髓瘤是美国，只是非淋巴瘤的常见类型的血癌形式。Hodgkin的ASCO还估计，美国约有32,270人在2020年之前患有多种骨髓瘤，预测治疗的需要。

Geographic Overview

North America dominated the global oncology clinical trials market, accounting for a revenue share of 55.0% in 2019. This can be attributed to an increase in R&D in the area, an increase in the implementation of emerging technologies in clinical science, and government funding.

For example, the FDA has responded to the call by adjusting to the way it reviews and approves new medicines for the unmet needs of severe diseases such as cancer. Various protocols, manuals, and programs have been established to accelerate the production and acceptance of safe and successful cancer drugs.

This covers clinical trials endpoints for the authorization of cancer medications and biologics; clinical trials endpoint imaging standards; FDA accelerated approval program; breakthrough therapy; accelerated approval; priority review; and swift follow-up.

竞争洞察力

几家制药公司在研发方面投入，特别是在发展中国家，以获得主要地区肿瘤临床试验的市场增长机会。预计医药公司和CRO之间的战略合作将对该部门的增长产生重大影响。

还有很少的玩家预计将在未来几年进入肿瘤学临床试验市场。例如，2019年9月，IQVIA宣布其与癌症研究人员合作，推进现实世界证据的使用并扩展肿瘤临床研究。

在全球肿瘤科学市场中运营的一些主要参与者包括Parexel International Corporation，PRA健康科学，Syneos Health，Medpace，Novotech，Pivotal，Icon Plc，Wuxi Apptec，Eli Lilly和Company，Novo Nordisk A / S，辉瑞和临床空间。